Fibromyalgia Therapeutics Pipeline Industry H1 2015 Review Report Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Fibromyalgia – Pipeline Review, H1 2015” report to its store. The report provides an overview of the fibromyalgia therapeutic pipeline.

Fibromyalgia Therapeutics Pipeline Industry

Fibromyalgia Therapeutics Pipeline Industry

The report “Fibromyalgia – Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Fibromyalgia. Fibromyalgia syndrome affects the muscles and soft tissue. Fibromyalgia is an extensively misunderstood and sometimes misdiagnosed chronic condition. Fibromyalgia is a general pain in the muscle but this syndrome causes many other symptoms. Symptoms of fibromyalgia include fatigue, brain fog, digestive disorders, pain all over, sleep difficulties, cramping, weakness, headaches, balance problems and burning skin. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/fibromyalgia-pipeline-review-h1-2015-market-report.html .

The report also reviews key players involved in the therapeutic development for fibromyalgia and special features on late-stage and discontinued projects. Companies discussed in this Fibromyalgia – Pipeline Review, H1 2015 report include Collegium Pharmaceutical, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Company, Merck & Co., Inc., Sumitomo Dainippon Pharma Co., Ltd., SWITCH Biotech LLC, Tonix Pharmaceuticals Holding Corp., Zynerba Pharmaceuticals, Inc.

Drugs profile discussed in this report include droxidopa, duloxetine hydrochloride dr, milnacipran hydrochloride, mirogabalin, mirtazapine, naltrexone, Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia, PRTT-200, SWT-06101, TD-9855, TNX-102 and ZYN-001.

Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=308863 . (This is a premium report priced at US$2000 for a single user License.)

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

“Featured News & Press Releases cover by this report include”: Jan 06, 2015: Tonix Pharmaceuticals Provides Clinical and Regulatory Update on its Continued Development of TNX-102 SL in Fibromyalgia; Sep 29, 2014: Tonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial of TNX-102 SL in Patients With Fibromyalgia; May 12, 2014: Tonix Pharmaceuticals Completes Enrollment in BESTFIT Trial of TNX-102 SL for Fibromyalgia; Apr 30, 2014: Theravance Announces Positive Results From a Phase 2 Study of TD-9855 in Patients With Fibromyalgia; Dec 10, 2013: Tonix Pharmaceuticals Announces the Enrollment of Completers From the BESTFIT Trial Into a 12-Month Open-Label Extension Study; Nov 26, 2013: Tonix Pharmaceuticals to Present at the Oppenheimer Healthcare Conference; Oct 11, 2013: Tonix Pharmaceuticals to Participate in the Women's Healthcare Innovation and Leadership Showcase on October 15, 2013; Sep 16, 2013: Tonix Pharmaceuticals Initiates Enrollment in Phase 2b BESTFIT Trial of TNX-102 SL in Fibromyalgia Patients; Aug 19, 2013: Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome; Mar 11, 2013: Tonix Completes Pre-Phase III Meeting With FDA For TNX-102 SL In Fibromyalgia.

Table of content

List of Tables
Number of Products under Development for Fibromyalgia, H1 2015 8
Number of Products under Development for Fibromyalgia - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
Fibromyalgia - Pipeline by Collegium Pharmaceutical, Inc., H1 2015 18
Fibromyalgia - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 19
Fibromyalgia - Pipeline by Eli Lilly and Company, H1 2015 20
Fibromyalgia - Pipeline by Merck & Co., Inc., H1 2015 21
Fibromyalgia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 22
Fibromyalgia - Pipeline by SWITCH Biotech LLC, H1 2015 23
Fibromyalgia - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2015 24
Fibromyalgia - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 25
Assessment by Monotherapy Products, H1 2015 26
Number of Products by Stage and Target, H1 2015 28
Number of Products by Stage and Mechanism of Action, H1 2015 30
Number of Products by Stage and Route of Administration, H1 2015 32
Number of Products by Stage and Molecule Type, H1 2015 34
Fibromyalgia Therapeutics - Recent Pipeline Updates, H1 2015 53
Fibromyalgia - Dormant Projects, H1 2015 67
Fibromyalgia - Discontinued Products, H1 2015 68

Explore more reports on Pain Management at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/pain-management .

About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@chinamrreport
Follow >
Market Reports China
Like >
Follow us on
Visit website